Rilpivirine - CAS# 500287-72-9 Catalog No.:M10762-2 Smiles: CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1C=CC=CC=1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O

Smiles: CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1C=CC=CC=1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O

Curr Mol Med

Smiles: COCCNCCC1=CC(=CC=C1)NC1N=C2C3=CC=CC=C3[C@@H](CC2=CN=1)C1=CC=CC=C1F

InChi: InChI=1S/C15H17IN2O2S

Rilpivirine - CAS# 500287-72-9 Catalog No.:M10762-2 Smiles: CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1C=CC=CC=1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=ORilpivirine is a pharmaceutical drug, developed by Tibotec, for the treatment of HIV infection. It is a second generation non nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half life and reduced side effect profile compared with older NNRTIs, such as efavirenz. Rilpivirine entered phase III clinical trials in April 2008, and was approved for use in the United States in May 2011. A fixed dose drug combining rilpivirine